• May 2026
  • Industry Analysis
THREE THINGS Q1 2026 MADE UNAMBIGUOUS
01
The industry chose margin over membership
Every national payer is repricing for margin and accepting volume loss to do it. UHG is shedding 1.3 million MA members on purpose. Aetna proved discipline two years running. Humana made it explicit: retention first, growth a distant third.
02
Benefit cuts for 2027 are now consensus
Every CEO confirmed the 2.48% rate notice does not cover trend. Vision, dental, gym, OTC, and Part B givebacks will compress across the industry. Reuters and Morningstar are already telling beneficiaries to expect leaner plans.
03
The operational gap is widening, fast
Alignment moved auto-adjudication from 15% to 60% in twelve months. Aetna processes 83% of prior auths in real time. UHG is investing $1.5B in AI this year. Plans without comparable investment are losing cost-to-serve ground.
7 of 7
payers signaled bid discipline for 2027
~3M
MA members in motion across the four nationals reducing footprint
2.48%
2027 net rate vs. observed trend running 7 to 10%
$3B+
in AI investment committed across UHG, Elevance, CVS in 2026

Seven Payers, One Page

For each payer: the Q1 story, the metrics that matter, the one quote that captures their posture, and the implication for your bid team, A side-by-side view of how each payer reported, where membership moved, and what each is now telegraphing for the 2027 bid cycle.

PAYER Q1 ADJ.
EPS		 MA
MEMBERSHIP		 MBR /
MCR		 2026 GUIDE
ACTION		 2027 BID POSTURE
UnitedHealth Group $7.23BEAT 9.7% ▼ 965K decline in Q1~1.3M full year guided 83.9%-90 BPS Raised $0.50 to >$18.25 Continued benefit rationalization. Aspiration: upper half of 2 to 4% MA margin range. 2027 rate "meaningfully below" trend.
Humana $10.31INLINE ▲ +23% YoY to 7.1M25% individual MA growth 89.4%+200 BPS Affirmed >$9.00 Most explicit of the seven. Benefit cuts coming, retention first, growth a distant third. 3% margin target by 2028.
Elevance Health $12.58BEAT 16% ▼ -15.8% YoY to 1.9MSharpest MA contraction 86.8%+40 BPS Raised $1.25 to ≥$26.75 ($1 non recurring) 2% MA margin target maintained. Continued bid discipline for 2027. Carries $935M CMS risk-adjustment accrual.
CVS Health (Aetna) $2.57BEAT 16% ▼ -1.1% to 4.2MIntentional contraction 84.6%-270 BPS Raised $0.30 to $7.30 to $7.50 Two consecutive years of margin-over membership. Target margins by 2028. STELARA biosimilar swap July 1.
Centene $3.37BEAT 58% ▼ ~1M, decliningD-SNP now 40% of MA book 84.9% (MA)-140 BPS Raised to >$3.40 MA breakeven path for 2027 confirmed. D-SNP concentration is the strategy. Not returning to AEP aggression yet.
Molina Healthcare $2.35BEAT 8.3% ▼ -3.1% to 229KExiting MAPD entirely for 2027 89.8% (Medicare)INLINE Reaffirmed ≥$5.00 Pivoting Medicare to dual-only (D-SNP, FIDE, HIDE). MAPD exit unlocks $1/share in 2027. Acuity shift "did not recur."
Alignment Healthcare $0.05BEAT 400% ▲ +30.9% YoY to 285K~50% growth in C-SNP, LIS, dual 88.2%-20 BPS Raised midpoint on all four guidance metrics The counter-cyclical case study. Growing into the national retreat with 100% of book at 4+ Stars. Large new markets in 2027.

WHAT THIS SCORECARD MAKES VISIBLE

Patterns the table surfaces at a glance

⬤

Six of seven posted EPS beats, but the nationals leaned heavily on reserve releases and Q1 seasonality that will not repeat in H2. Underlying improvement is real but smaller than the headlines suggest.

⬤

Six of seven accepted MA membership decline as the cost of margin recovery. Only Humana grew, and it grew into a 2027 benefit-cut commitment. Most disciplined the industry has been in a decade.

⬤

Two payers are running a fundamentally different playbook. Molina is exiting MAPD entirely to focus on duals. Alignment is growing 30% with a clinical-first model. Both are templates worth studying.

Peer Briefs: The Big Four Nationals

For each payer: the Q1 story, the metrics that matter, the one quote that captures their posture, and the implication for your bid team

UnitedHealth Group
TURNAROUND
First credible inflection point in a 12-month turnaround narrative.
ADJ. EPS
$7.23
beat 9.7%
REVENUE
$111.7B
+2%
MCR
83.9%
-90 bps
MA MEMBERSHIP
-965K
in Q1
“We are really comfortable with the pricing posture we had coming into 2026.”
TIM NOEL, CEO, UNITEDHEALTHCARE
FOR YOUR BID TEAM
Q1 beat was powered by ~$500M in reserve releases. Q2 is the clean test. UHG's 1.3M MA exit creates the largest single switcher pool in the market for AEP 2027, concentrated where benefits were repriced hardest.
Humana
REPRICING
The most explicit 2027 bid-discipline signal of any payer this season.
ADJ. EPS
$10.31
in line
MA MEMBERSHIP
7.1M
+23% YoY
INSURANCE BR
89.4%
+200 bps
2026 SEGMENT INCOME
~Breakeven
Stars drag
“The priority is retention, retention, retention. Growth is a distant third priority.”
JIM RECHTIN, CEO, HUMANA
FOR YOUR BID TEAM
Humana is openly cutting benefits market by market for 2027 to hit 3% margin by 2028. October BY2027 Stars announcement is the binary event for Humana's trajectory and the broader AEP 2027 competitive map.
Elevance Health
MIXED SIGNAL
Strong beat with hidden anatomy. $935M CMS accrual is the new industry signal.
ADJ. EPS
$12.58
beat 16%
REVENUE
$49.5B
+1.5%
BER
86.8%
+40 bps
MA MEMBERSHIP
1.9M
-15.8% YoY
“We are not relying on a different trend environment to support the guide.”
GAIL BOUDREAUX, CEO, ELEVANCE HEALTH
FOR YOUR BID TEAM
$1.00 of the $1.25 EPS raise is non-recurring. Real underlying outperformance is closer to $0.30. Elevance is the second major payer to disclose a material CMS risk-adjustment accrual. Plans should review their own RAF exposure now.
CVS Health (Aetna)
RECOVERY
Cleanest Aetna recovery print in two years. Discipline is now the operating model.
ADJ. EPS
$2.57
beat 16%
REVENUE
$100.4B
+6.2%
MBR
84.6%
-270 bps
MA MEMBERSHIP
4.2M
-1.1%
“Two consecutive years prioritizing margin over growth.”
DAVID JOYNER, CEO, CVS HEALTH
FOR YOUR BID TEAM
Aetna is not coming back as an AEP aggressor in 2027. Markets where Aetna is repricing benefits or exiting service areas are direct switcher opportunities. STELARA biosimilar swap July 1 reshapes specialty drug economics for Caremark plans.

Peer Briefs: The Strategic Pivots

Three payers whose Q1 stories are less about earnings and more about portfolio reshaping that will define the 2027 to 2028 competitive map.

Centene
PIVOTING
Margin recovery gaining traction across all three segments. D-SNP is the strategy.
ADJ. EPS
$3.37
beat 58%
REVENUE
$49.9B
+7.1%
MEDICARE HBR
84.9%
-140 bps
D-SNP SHARE OF MA
40%
growing
“We continue to see a path to delivering break-even financial results next year.”
SARAH LONDON, CEO, CENTENE
FOR YOUR BID TEAM
Third consecutive quarter of Medicaid HBR improvement. June Wakely Marketplace data is the next catalyst. Centene staying out of aggressive AEP for 2026 to 2027 creates geographic windows where Centene rationalized standard MA.
Molina Healthcare
PIVOTING
The cleanest signal that the post-pandemic acuity shift is structurally over.
ADJ. EPS
$2.35
beat 8.3%
PREMIUM REVENUE
$10.2B
-4%
MEDICAID MCR
89.8
favorable
2027 MAPD
Exiting
+$1/share unlock
“The 2.5% acuity shift component of trend for 2025 did not recur.”
JOE ZUBRETSKY, CEO, MOLINA HEALTHCARE
FOR YOUR BID TEAM
Molina's data signals Medicaid trend is normalizing industry-wide, easing 2027 state rate pressure. MAPD exit creates displaced members in CA and the Northeast, particularly D-SNP-eligible populations Molina will retain and grow.
Alignment Healthcare
COUNTER-CYCLICAL
The case study. Growing 31% into the national retreat with 100% at 4+ Stars.
ADJ. EPS
$0.05
beat 400%
REVENUE
$1.24B
+33% YoY
MBR
88.2%
-20 bps
MA MEMBERSHIP
285K
+30.9% YoY
“Year-to-date claims auto-adjudication rate is over 60%.”
JOHN KAO, CEO, ALIGNMENT HEALTHCARE
FOR YOUR BID TEAM
Confirmed entry into "some large markets" for 2027. Roughly 50% of AEP growth came from C-SNP, LIS, and duals. The clinical-first, dual-focused, Stars-leading model is the template that will get harder to compete against.
The Comparative Read
SYNTHESIS
Two distinct strategies are emerging across the seven payers, and they will define how AEP 2027 plays out.
STRATEGY A · DEFEND AND REPRICE
UHG, Humana, Elevance, CVS. Cut benefits, accept membership loss, target 2 to 3% MA margin by 2028. Stars and operational scale do the heavy lifting.
STRATEGY B · SPECIALIZE AND GROW
Centene, Molina, Alignment. Rotate to dual-eligible, exit unprofitable lines, lean into clinical model. Growth where the model wins, restraint elsewhere.
The 2027 winners will likely come from both camps. The losers will be the plans pursuing neither.

What This Means for Your Bid Team

Four plays the Q1 data supports. None are new ideas. All are now commercially actionable in a way they were not 90 days ago.

PLAY 01
Treat AEP 2027 as a switcher market, not a share-take market
Roughly 3M MA members are in motion across UHG, Humana, and Elevance reductions. The strategic question shifts from "how do we steal share" to "where are competitors leaving members exposed."
COUNTY-LEVEL COMPETITIVE MAP BY JULY
PLAY 02
Stars is now the single largest lever in your bid
October BY2027 Stars will reshape competitive economics for at least three nationals. If you are at four stars, you have an asymmetric moment. If below, every operational dollar should fund HEDIS and CAHPS.
LOCK STARS INVESTMENT PLAN BEFORE Q3
PLAY 03
Audit your risk-adjustment posture before CMS does
Two of the largest payers now carry material accruals for historical RA practices. Plans with similar coding profiles or in home assessment dependencies should commission an independent review now.
INDEPENDENT RAF AND HCC REVIEW BY Q3
PLAY 04
Make the D-SNP decision now, not in 2028
Every national is rotating toward dual. Molina is going dual-only. Members, network economics, and CMS regulatory tailwinds all point to D-SNP as the durable franchise.
D-SNP ROADMAP WITH Q4 MILESTONE
THE 90-DAY WATCHLIST
JUNE 2, 2026
CY2027 Bid Submission Deadline
The shape of 2027 plans, including all benefit reductions discussed on these calls, gets locked. Scenario modeling should be complete before this date.
MID-JUNE 2026
Wakely Marketplace Data
Key catalyst for Centene's Marketplace receivable thesis and the broader silver-tier acuity-shift narrative. Confirms or resets the read.
LATE JULY 2026
Q2 2026 Earnings Begin
The clean test. Q2 numbers arrive without the Q1 reserve releases. Margin trajectories at UHG, Aetna, Elevance get validated or reset.
JULY 31, 2026
Elevance CMS Compliance
The procedural test for the second wave of CMS RA enforcement. Clean resolution sets the template. Complication signals broader exposure.
AUGUST 2026
State Medicaid Rate Cycles
Multiple state processes finalize through July and August. Closes (or doesn't) the Medicaid rate-to-trend gap for 2027.
OCTOBER 2026
BY2027 Stars Announcement
The single largest binary event in the MA calendar. Reshapes 2028 economics at Humana most acutely, with knock-on effects across the industry.

Your Network Is Your Stars Strategy

Book a complimentary Star Rating + Network Review with our team.

Trusted by 25+ Medicare Advantage payers

Request Your Review →

Published by HealthWorksAI

Request A Personalized Demo
Let us show you how HealthWorksAI can optimize your Medicare Advantage product design efforts at every stage through actionable insights by leveraging public and private healthcare data.